Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ABGLF OTCMKTS:CLIGF OTCMKTS:FXCNY OTCMKTS:POFCY OTCMKTS:ZLDPF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABGLFAcacia Mining$3.09$3.09$1.99▼$3.09$1.27BN/A32,275 shsN/ACLIGFClinigen Group$8.02$8.02$8.02▼$11.56$1.07B0.498,620 shsN/AFXCNYFIH Mobile$13.25$8.40$1.50▼$2.67$5.22BN/A968 shsN/APOFCYPetrofac$0.12$0.12$0.02▼$3.27$121.75M2.77N/AN/AZLDPFZealand Pharma A/S$57.56-3.4%$64.15$54.95▼$141.74$4.09B0.68931 shs120 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABGLFAcacia Mining0.00%0.00%0.00%0.00%0.00%CLIGFClinigen Group0.00%0.00%0.00%0.00%0.00%FXCNYFIH Mobile-0.53%+12.29%+12.29%+728.13%+562.50%POFCYPetrofac0.00%0.00%0.00%+230.75%+42.89%ZLDPFZealand Pharma A/S0.00%+3.13%-21.40%-4.70%-57.46%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABGLFAcacia MiningN/AN/AN/AN/AN/AN/AN/AN/ACLIGFClinigen GroupN/AN/AN/AN/AN/AN/AN/AN/AFXCNYFIH MobileN/AN/AN/AN/AN/AN/AN/AN/APOFCYPetrofacN/AN/AN/AN/AN/AN/AN/AN/AZLDPFZealand Pharma A/SN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABGLFAcacia Mining 0.00N/AN/AN/ACLIGFClinigen Group 0.00N/AN/AN/AFXCNYFIH Mobile 0.00N/AN/AN/APOFCYPetrofac 0.00N/AN/AN/AZLDPFZealand Pharma A/S 3.80Strong BuyN/AN/ACurrent Analyst Ratings BreakdownLatest CLIGF, ZLDPF, POFCY, ABGLF, and FXCNY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/7/2025ZLDPFZealand Pharma A/SBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/1/2025ZLDPFZealand Pharma A/SBNP ParibasSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABGLFAcacia MiningN/AN/AN/AN/AN/AN/ACLIGFClinigen Group$704.71M1.51$1.43 per share5.60$4.52 per share1.77FXCNYFIH Mobile$6.45B0.81$0.42 per share31.43$3.96 per share3.35POFCYPetrofac$2.50B0.05N/AN/A($0.42) per share-0.27ZLDPFZealand Pharma A/S$9.09M449.74N/AN/A$17.59 per share3.27Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABGLFAcacia MiningN/AN/A0.00∞N/AN/AN/AN/AN/ACLIGFClinigen Group$40.78MN/A0.00∞N/AN/AN/AN/AN/AFXCNYFIH Mobile-$120.68MN/A0.00∞N/AN/AN/AN/A8/7/2025 (Estimated)POFCYPetrofac-$505MN/A0.002.88N/AN/AN/AN/AN/AZLDPFZealand Pharma A/S-$156.43M-$2.49N/AN/AN/A-2,127.09%-13.40%-12.28%8/13/2025 (Estimated)Latest CLIGF, ZLDPF, POFCY, ABGLF, and FXCNY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025ZLDPFZealand Pharma A/S-$0.77-$0.67+$0.10-$0.67$248.61 million$1.14 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABGLFAcacia MiningN/AN/AN/AN/AN/ACLIGFClinigen GroupN/AN/AN/AN/AN/AFXCNYFIH Mobile$0.060.48%N/AN/AN/APOFCYPetrofacN/AN/AN/AN/AN/AZLDPFZealand Pharma A/SN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABGLFAcacia MiningN/AN/AN/ACLIGFClinigen GroupN/AN/AN/AFXCNYFIH MobileN/A1.220.83POFCYPetrofacN/AN/AN/AZLDPFZealand Pharma A/S0.0325.1025.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABGLFAcacia MiningN/ACLIGFClinigen GroupN/AFXCNYFIH MobileN/APOFCYPetrofacN/AZLDPFZealand Pharma A/SN/AInsider OwnershipCompanyInsider OwnershipABGLFAcacia MiningN/ACLIGFClinigen GroupN/AFXCNYFIH MobileN/APOFCYPetrofacN/AZLDPFZealand Pharma A/SN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABGLFAcacia Mining1,331410.09 millionN/ANot OptionableCLIGFClinigen Group1,069133.03 millionN/ANot OptionableFXCNYFIH Mobile6,657394.12 millionN/ANot OptionablePOFCYPetrofac8,1911.06 billionN/ANot OptionableZLDPFZealand Pharma A/S34071.02 millionN/ANot OptionableCLIGF, ZLDPF, POFCY, ABGLF, and FXCNY HeadlinesRecent News About These CompaniesZealand Pharma A/S (OTCMKTS:ZLDPF) Stock Rating Upgraded by BarclaysJuly 9 at 7:35 AM | marketbeat.comZealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up - Here's WhyJuly 8 at 3:08 PM | marketbeat.comZealand Pharma A/S (OTCMKTS:ZLDPF) Rating Increased to Strong-Buy at BNP ParibasJuly 4, 2025 | marketbeat.comFinancial Review: Zealand Pharma A/S (ZLDPF) & Its CompetitorsJuly 3, 2025 | americanbankingnews.comZealand Pharma A/S (OTCMKTS:ZLDPF) Sets New 52-Week Low - Time to Sell?June 30, 2025 | marketbeat.comZealand Pharma A/S (OTCMKTS:ZLDPF) Reaches New 52-Week Low - Should You Sell?June 24, 2025 | marketbeat.comZealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down - Here's WhyJune 20, 2025 | marketbeat.comZealand Pharma A/S (OTCMKTS:ZLDPF) Sets New 52-Week Low - Here's What HappenedJune 17, 2025 | marketbeat.comCantor Fitzgerald Comments on OTCMKTS:ZLDPF FY2026 EarningsJune 12, 2025 | marketbeat.comFY2025 EPS Forecast for Zealand Pharma A/S Raised by AnalystJune 11, 2025 | marketbeat.comZealand CEO: Oral weight loss meds are not the future for treating obesityMay 15, 2025 | seekingalpha.comZealand Pharma A/S (ZLDPF) Q1 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comZealand Pharma AS (ZLDPF) Q1 2025 Earnings Call Highlights: Strategic Collaborations and ...May 9, 2025 | finance.yahoo.comInside the deal: Roche and Zealand Pharma's $5.3 billion obesity drug gambitMay 2, 2025 | cnbc.comZealand Pharma AS (ZLDPF) Stock Jumps 8.0%: Will It Continue to Soar?May 1, 2025 | zacks.comZealand Pharma begins mid-stage trial for obesity drug candidate in people with type 2 diabetesApril 24, 2025 | reuters.comZealand Pharma appoints Utpal Singh as Chief Scientific OfficerApril 23, 2025 | contractpharma.comCZealand Pharma appoints Utpal Singh as CSOApril 23, 2025 | markets.businessinsider.comZealand Pharma Hires Lilly Executive as Biotech Ramps Up in ObesityApril 23, 2025 | msn.comZealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2025April 19, 2025 | finance.yahoo.comZealand Pharma Goes on Hiring Spree as It Gears Up for Obesity Tie-Up With RocheApril 11, 2025 | wsj.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCLIGF, ZLDPF, POFCY, ABGLF, and FXCNY Company DescriptionsAcacia Mining OTCMKTS:ABGLF$3.09 0.00 (0.00%) As of 05/12/2021Acacia Mining plc, together with its subsidiaries, mines, processes, and sells gold in Africa. The company has three gold mines in north-west Tanzania, including Bulyanhulu, Buzwagi, and North Mara; and a portfolio of exploration projects at various stages of development in Tanzania, Kenya, Burkina Faso, and Mali. It also produces co-products, such as copper and silver. The company was formerly known as African Barrick Gold plc and changed its name to Acacia Mining plc in November 2014. The company was incorporated in 2010 and is headquartered in London, the United Kingdom. Acacia Mining plc is a subsidiary of Barrick Gold Corporation.Clinigen Group OTCMKTS:CLIGF$8.02 0.00 (0.00%) As of 03/24/2023Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through Services and Products divisions. The company provides a set of niche and high value services to pharma and biotech clients prior to product launch. It also provides access to critical medicines around the world for patients with unmet needs. In addition, the company provides a portfolio of specialist medicines to service the needs of healthcare professionals and their patients in both licensed and unlicensed markets. Further, it offers Nortriptyline Colonis for the treatment of depressive disorder; Metformin Colonis for the treatment of type 2 diabetes mellitus; Magnesium Chewable Tablets, an oral magnesium supplements for the treatment of patients with chronic magnesium loss; Iloprost, a concentrate for solution for infusion; Glycopyrronium Bromide, an oral solution for the treatment of severe sialorrhoea; Acetylcysteine, an oral solution for the treatment of respiratory disorders associated with thick, viscous, and mucus hypersecretion; Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Proleukin for the treatment of kidney cancer; Imukin that is used in chronic granulomatous disease; Totect, a dexrazoxane product; Foscavir, an anti-virals that work by stopping viruses from multiplying in number; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.FIH Mobile OTCMKTS:FXCNY$13.25 0.00 (0.00%) As of 07/10/2025FIH Mobile Limited, an investment holding company, provides integrated manufacturing services for the handset industry worldwide. The company designs, manufactures, and trades in handsets, as well as offers repair services. It is also involved in the research and development activity; manufacture and sale of electronic products; and import and export activities. The company was formerly known as Foxconn International Holdings Limited and changed its name to FIH Mobile Limited in May 2013. FIH Mobile Limited was incorporated in 2000 and is headquartered in New Taipei City, Taiwan. FIH Mobile Limited is a subsidiary of Foxconn (Far East) Limited.Petrofac OTCMKTS:POFCY$0.12 0.00 (0.00%) As of 07/10/2025Petrofac Limited designs, builds, manages, and maintains infrastructure for the energy industries in the United Kingdom, Algeria, Thailand, Oman, Kuwait, Iraq, the United Arab Emirates, the Netherlands, and internationally. It operates through three segments: Engineering & Construction (E&C); Asset Solutions; and Integrated Energy Services (IES). The E&C segment provides onshore and offshore engineering, procurement, construction, installation, and commissioning services. The Asset Solutions segment offers concept, feasibility, and front-end engineering design services, as well as manages and maintains onshore and offshore operations. The IES segment focuses on delivering value from the existing asset portfolio. The company was founded in 1981 and is based in St Helier, Jersey.Zealand Pharma A/S OTCMKTS:ZLDPF$57.56 -2.00 (-3.36%) As of 10:59 AM EasternZealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
